Ointment broke 6 billion for the first time, and the TOP10 sold well! Only 3 varieties have been reviewed

As a dosage form for transdermal administration, ointment is widely used
in dermatology and surgery in hospitals.
Since the beginning of this year, only Hubei Heng'an Fulin Pharmaceutical's tacrolimus ointment has been approved as imitation of 4 categories, which is regarded as over-evaluation
.
At present, only 3 varieties of ointments have been evaluated
.
Intranet data shows that in 2021, the sales scale of terminal ointment chemicals in China's public medical institutions exceeded the 6 billion yuan mark for the first time, and the TOP10 products rose across the board, with Winbond, Australia and the United States and Tongfang seizing the top three
.
Since 2019, 13 varieties (29 acceptance numbers) have been reported under review in the new classification, of which 5 varieties have not been approved by domestic generic drug enterprises, and Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical and Fuyuan Pharmaceutical are expected to win the first imitation
.
In addition, 10 Class 1 new drugs have been approved clinically
.

 

Ointment first broke 6 billion! Only 3 varieties have been reviewed

 

Sales of terminalized pharmaceutical ointments in China's public medical institutions in recent years (:100 million yuan)

Source: Intranet China's public medical institutions terminal competition pattern

 

As a dosage form for transdermal administration, ointment can not only avoid the destruction of drugs in the gastrointestinal tract, reduce the peak and trough changes of blood drug concentration, but also become one of the effective ways to overcome drug side effects, and are widely used
in dermatology and surgery in hospitals.

 

According to Intranet data, in recent years, the market size of terminal ointment chemicals in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) has steadily increased, slightly declined due to the impact of the epidemic in 2020, and rebounded sharply in 2021, with sales exceeding the 6 billion yuan mark
for the first time.

 

Since the beginning of this year, only Hubei Heng'an Fulin Pharmaceutical's tacrolimus ointment has been approved as imitation of 4 categories, which is regarded as over-evaluation and is the second enterprise
to be evaluated for the product.
It is understood that Hubei Heng'an Fulin Pharmaceutical focuses on the development of drugs in the field of skin, has developed and launched a series of products covering the treatment of dermatitis, eczema, antifungal, antiviral and other products, and is one of the professional preparation enterprises with many varieties of
preparations at home and abroad, full categories and high-end products.

 

Ointment over-evaluation

Source: New version of the database of Intranet

 

Up to now, only 3 varieties (4 specifications) of ointments have been evaluated, among which Mopirocin ointment of Fuyuan Pharmaceutical and Tacarcinol ointment of Nanjing Hairong Pharmaceutical have been exclusively evaluated
.
It is worth mentioning that no ointment is pending
in the consistency evaluation supplement application.

 

TOP10 all online! 4 products rose by more than 20%, and Winbond, Australia and the United States, and Tongfang grabbed the top three

 

In 2021, China's public medical institutions terminal drug ointment products TOP10

Source: Intranet China's public medical institutions terminal competition pattern

 

The TOP10 products rose across the board, and 8 had double-digit growth rates, among which tacrolimus ointment, reproxicaine cream (compound lidocaine cream), fluticasone propionate cream and mopirocin ointment all had a growth rate
of more than 20%.
From the perspective of treatment categories, dermatological drugs occupy the mainstream
.

 

In 2021, China's public medical institutions terminal ointment pharmaceutical brand TOP10

 

Source: Among the top 10 brands in the terminal competition pattern of China's public medical institutions in China, Chongqing Winbond Pharmaceutical's Deinert Cream, Aomei Pharmaceutical's Halomethasone Cream, and Tongfang Pharmaceutical Group's Compound Lidocaine Cream ranked in the top three
.
In terms of quantity, Aomei Pharmaceutical has the most, with 2 on the list
.

 

Sales of terminal tacrolimus ointment in public medical institutions in China in recent years (:100 million yuan)

Source: Intranet China's public medical institutions terminal competition pattern

 

Tacrolimus ointment is indicated as a short-term or intermittent long-term treatment in patients with moderate to severe atopic dermatitis who are not suitable for traditional therapy due to potential dangers, or who do not respond adequately to conventional therapy, or who do not respond adequately to conventional therapy
.
Intranet data show that tacrolimus ointment in 2021 China's public medical institutions terminal sales of more than 400 million yuan, is the ointment TOP1 products, there are currently 10 companies have production approvals, Hangzhou Sino-American Huadong Pharmaceutical | Zhejiang Thermo Pharmaceutical, Fuyuan Pharmaceutical, Shenyang Sansheng Pharmaceutical| Zhejiang Wansheng Pharmaceutical and other 5 reported production in the trial, the future market competition will be more intense
.

 

Yangtze River, Fuyuan.
.
.
The impact of the first imitation, 10 Class 1 new drugs are fiercely coming

 

Since 2019, the chemical ointment has been submitted for production

Source: MED2.
0 China Drug Review Database

 

Since 2019, 13 ointments (29 acceptance numbers) have been submitted for trial in the new classification, which will set off a wave of
evaluation.
From the product point of view, lipropylene double caine cream (compound lidocaine cream) is the most popular, involving Sichuan Haisike, Hubei Renfu Chengtian Pharmaceutical and other 8 enterprises, at present, the domestic approval is only 1 Tongfang Pharmaceutical Group
.
From the perspective of enterprises, Fuyuan Pharmaceutical and Aomei Pharmaceutical have the largest number of products, with 3 each
.
Fusidiol cream, pimecrolimus cream, difluranolone valerate cream, neconazole hydrochloride cream, vitamin quinone cream domestic no generic drug enterprises have been approved, Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical, Fuyuan Pharmaceutical, Tianjin Jinyao Pharmaceutical, etc.
are expected to win the first imitation
.

 

Since 2019, the clinical situation of chemical ointment class 1 new drugs has been approved

Source: MED2.
0 China Drug Review Database

 

In addition, 10 new ointment drugs of class 1 have been approved clinically, involving therapeutic categories such as dermatological drugs, anti-tumor and immunomodulators
.

 

EG017 ointment indications for postmenopausal women dry eye, in August this year, Changchun Gaoxin issued an announcement that its holding subsidiary Changchun Kinsey Pharmaceutical Co.
, Ltd.
1 class 1 new drug EG017 ointment 4 specifications were approved clinically
.
Changchun High-tech said that if the product is approved for listing, it will further broaden the company's business structure, enrich and improve the layout of product lines in strategic areas, and enhance core competitiveness
.

 

Jacktinib hydrochloride cream is a topical JAK kinase small molecule inhibitor independently developed by Zejing Pharmaceutical, which belongs to Class 1 innovative drugs, and its indications for the treatment of mild to moderate alopecia areata (topical) and mild to moderate atopic dermatitis (topical) are in the phase
I / II clinical trials.

 

Source: Intranet database, company announcements

 

Note: Minet's "Terminal Competition Pattern of China's Public Medical Institutions", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.